trial · primary record
Dovramilast
Erythema Nodosum Leprosum
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 45 |
| Primary completion | 2028-07 |
| Primary endpoint | The proportion of dovramilast (100 mg or 150 mg) recipients achieving a 75% improvement in leprosy type 2 reaction skin lesions at week 12 |
| Registry ID | NCT07172659 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:07.237Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07172659
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.